Zuco V - Search Results

1

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.

Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Zuco V, et al. J Exp Clin Cancer Res. 2021 Mar 1;40(1):83. doi: 10.1186/s13046-021-01886-x. J Exp Clin Cancer Res. 2021. PMID: 33648535 Free PMC article.

2

Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.

Zuco V, Benedetti V, De Cesare M, Zunino F. Zuco V, et al. Int J Cancer. 2010 Mar 1;126(5):1246-55. doi: 10.1002/ijc.24819. Int J Cancer. 2010. PMID: 19676051 Free article.

3

Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C, Zunino F. Zuco V, et al. Biochem Pharmacol. 2010 Feb 15;79(4):535-41. doi: 10.1016/j.bcp.2009.09.012. Biochem Pharmacol. 2010. PMID: 19765546

4

Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.

Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F. Pisano C, et al. Among authors: zuco v. Clin Cancer Res. 2010 Aug 1;16(15):3944-53. doi: 10.1158/1078-0432.CCR-10-0964. Epub 2010 Jun 18. Clin Cancer Res. 2010. PMID: 20562210

5

Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.

Zuco V, De Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F. Zuco V, et al. PLoS One. 2011;6(12):e29085. doi: 10.1371/journal.pone.0029085. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194993 Free PMC article.

6

Targeting DNA topoisomerase I with non-camptothecin poisons.

Beretta GL, Zuco V, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zuco v. Curr Med Chem. 2012;19(8):1238-57. doi: 10.2174/092986712799320529. Curr Med Chem. 2012. PMID: 22204335 Review.

7

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F. Cassinelli G, et al. Among authors: zuco v. Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13. Biochem Pharmacol. 2012. PMID: 22525722

8

Namitecan: a hydrophilic camptothecin with a promising preclinical profile.

Beretta GL, Zuco V, De Cesare M, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zuco v. Curr Med Chem. 2012;19(21):3488-501. doi: 10.2174/092986712801323252. Curr Med Chem. 2012. PMID: 22680917 Review.

9

Drug combinations with proteasome inhibitors in antitumor therapy.

Gatti L, Zuco V, Zaffaroni N, Perego P. Gatti L, et al. Among authors: zuco v. Curr Pharm Des. 2013;19(22):4094-114. doi: 10.2174/1381612811319220015. Curr Pharm Des. 2013. PMID: 23181571 Review.

10

Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.

Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Cassinelli G, et al. Among authors: zuco v. Curr Med Chem. 2013;20(15):1923-45. doi: 10.2174/09298673113209990106. Curr Med Chem. 2013. PMID: 23410153 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page